Sanofi/Lexicon's sotagliflozin filed in US and EU for type 1 diabetes
Regulators in the US and Europe are to review Sanofi/Lexicon’s sotagliflozin in type 1 diabetes, a potential blockbuster pill.
The French firm is trying to rebuild sales following loss of patent protection on its big-selling insulin, Lantus, and the filings with the FDA and European Medicines Agency are therefore an important development.
If approved, sotagliflozin would be used as an addition to insulin therapy to improve blood sugar control in adults with type 1 diabetes mellitus.
A dual inhibitor of SGLT-1 and SGLT-2, sotagliflozin has been developed to influence how the intestines and kidneys process blood sugar.
Consensus forecasts from EvaluatePharma suggest sotaglifozin could have sales of $1.16 billion by 2022.
Sanofi will not see all of that revenue as sotaglifozin was developed in partnership with the US biotech Lexicon.
Lexicon got $300 million up front when the collaboration began in 2015, and will receive development, regulatory and sales milestone payments of up to $1.4 billion.
It will also receive tiered, escalating double-digit percentage royalties on net sales of sotaglifozin.
Sanofi has an exclusive worldwide licence to develop, manufacture and market sotaglifozin, excluding Japan, although Lexicon has taken an option to co-promote the drug in the US.
Lexicon took responsibility for clinical development of sotaglifozin in type 1 disease, while Sanofi is to develop and market it in type 2 disease. Lexicon agreed to provide funding of up to $100 million towards development in type 2 disease.
Sanofi’s global head of development, Jorge Insuasty, said: “Despite recent advances, the challenges of type 1 diabetes management prevent many patients from reaching their treatment goals. There is a need for therapies to be used in addition to insulin to help people with type 1 diabetes better control their blood sugar. Sotagliflozin is the first SGLT-1/2 dual inhibitor to be accepted for regulatory review in Europe.”
Lexicon's Pablo Lapuerta
Lexicon’s chief medical officer, Pablo Lapuerta, said: “These filings highlight our strong investment in internally-discovered therapies and are a culmination of the largest phase 3 programme for an oral anti-diabetic agent ever conducted in type 1 diabetes, in the broadest range of patients, resulting in the most comprehensive efficacy and safety database. I am extremely proud of our team members who have worked tirelessly to achieve this step towards bringing this important potential therapy to patients with type 1 diabetes.”
The filing is based on data from the inTandem clinical trial programme, which consists of three phase 3 clinical trials assessing the safety and efficacy of sotagliflozin in approximately 3,000 adults with inadequately-controlled type 1 diabetes.
